Merck sells Théramex to Teva

Merck KGaA has agreed to sell Théramex, its Monaco-based pharmaceutical company specialized in women’s health and gynecology, to Teva.

Merck KGaA has agreed to sell Théramex, its Monaco-based pharmaceutical company specialized in women’s health and gynecology, to Teva. Merck and Teva have signed an agreement whereby Teva will acquire all Théramex operations including 100% of the shares of Théramex S.A.M of Monaco and Théramex S.p.A. of Italy for a consideration of €265 million. In addition, Merck will be eligible to receive certain performance-based milestone payments. Teva will have the distribution rights of Théramex products in certain countries including Spain and Brazil; Merck Serono will continue distributing Théramex products in certain other countries.

The divested Théramex business represents about €100 million of sales in 2009, including sales in the countries where distribution rights will be acquired by